Europe Melanoma Therapeutics Market by cancer stage (Stage 0, Stage I, Stage II, Stage III, Stage IV), by cancer type (Nodular melanoma, Acral lentiginous melanoma, Superficial spreading melanoma, Lentigno maligna melanoma, Amelanotic melanoma, Others), by diagnosis (Ultrasound, Blood Tests, Dermatoscopy, Sentinel lymph node biopsy, X-rays, CT Scan), by treatment (early melanoma, advanced melanoma-Biological therapy, Targeted therapy, Surgery, Chemotherapy, Radiotherapy, Immune therapy) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Europe Melanoma Therapeutics Market by cancer stage (Stage 0, Stage I, Stage II, Stage III, Stage IV), by cancer type (Nodular melanoma, Acral lentiginous melanoma, Superficial spreading melanoma, Lentigno maligna melanoma, Amelanotic melanoma, Others), by diagnosis (Ultrasound, Blood Tests, Dermatoscopy, Sentinel lymph node biopsy, X-rays, CT Scan), by treatment (early melanoma, advanced melanoma-Biological therapy, Targeted therapy, Surgery, Chemotherapy, Radiotherapy, Immune therapy) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 852 | Pages: 133 | November 2016 | Region: Europe


The Europe Melanoma Therapeutics Market was worth $0.54 billion in 2016 and estimated to be growing at a CAGR of 16.20%, to reach $1.13 billion by 2021. The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.

Melanoma denotes to the type of skin cancer which forms from the pigment-consisting cells in the skin. The elevated demand of innovative early stage and advanced melanoma treatments along with a thriving patient base, has generated an imminent need for improved therapies in the melanoma market. Even though, a plethora of treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive in the market.

Rise in Melanoma cases is one of the major driver for the Melanoma Therapeutics market in this region. Other factors such as high acceptance rate of therapeutics among patients, and government policies to provide better care for melanoma also drive the market in this region. However, high costs incurred due to treatment is one of the major factor hindering the growth of the market in this region.

The Europe Melanoma Therapeutics market is segmented based on cancer stage, cancer type, diagnosis, and treatment. The market for Melanoma Therapeutics, on the basis of cancer stage is segmented into Stage 0, Stage I, Stage II, Stage III, Stage IV. On the basis of cancer type, the Melanoma Therapeutics market is segmented into Nodular melanoma, Acral lentiginous melanoma, Superficial spreading melanoma, Lentigno maligna melanoma, Amelanotic melanoma, and Others. On the basis of diagnosis, the Melanoma Therapeutics market is segmented into Ultrasound, Blood Tests, Dermatoscopy, Sentinel lymph node biopsy, X-rays, CT Scan. On the basis of treatment, the Melanoma Therapeutics market is segmented into early melanoma and advanced melanoma. Advanced melanoma is further sub-segmented into Biological therapy, Targeted therapy, Surgery, Chemotherapy, Radiotherapy, Immune therapy. X-rays leads the Melanoma Therapeutics market under the diagnosis segment, whereas chemotherapy leads the market under the treatment segment.

The Europe Melanoma Therapeutics market has been geographically segmented into Germany, U.K, France, Spain, and Italy. The Europe Melanoma Therapeutics market is the third largest market with a global share of 24%. UK is the largest market share holder for the Melanoma Therapeutics market in this region, followed by Germany and France.

The major companies dominating the market in this region are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 U.K               

              6.3 Spain                          

              6.4 Germany                   

              6.5 Italy                            

              6.6 France                       

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

TitlePriceAdd To Cart
  1. Europe Melanoma Therapeutics Market By Region, From 2016-2021 (USD Billion)
  2. Europe Melanoma Therapeutics Market By Cancer stage , From 2016-2021 (USD Billion)
  3. Europe Stage 0 Market By Region, From 2016-2021 (USD Billion)
  4. Europe Stage I Market By Region, From 2016-2021 (USD Billion)
  5. Europe Stage II Market By Region, From 2016-2021 (USD Billion)
  6. Europe Stage III Market By Region, From 2016-2021 (USD Billion)
  7. Europe Stage IV Market By Region, From 2016-2021 (USD Billion)
  8. Europe Melanoma Therapeutics Market By Cancer type , From 2016-2021 (USD Billion)
  9. Europe Nodular melanoma Market By Region, From 2016-2021 (USD Billion)
  10. Europe Acral lentiginous melanoma Market By Region, From 2016-2021 (USD Billion)
  11. Europe Superficial spreading melanoma Market By Region, From 2016-2021 (USD Billion)
  12. Europe Lentigno maligna melanoma Market By Region, From 2016-2021 (USD Billion)
  13. Europe Amelanotic melanoma Market By Region, From 2016-2021 (USD Billion)
  14. Europe Other cancers Market By Region, From 2016-2021 (USD Billion)
  15. Europe Melanoma Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  16. Europe Ultrasound Market By Region, From 2016-2021 (USD Billion)
  17. Europe Blood Tests Market By Region, From 2016-2021 (USD Billion)
  18. Europe Dermatoscopy Market By Region, From 2016-2021 (USD Billion)
  19. Europe Sentinel lymph node biopsy Market By Region, From 2016-2021 (USD Billion)
  20. Europe X-rays Market By Region, From 2016-2021 (USD Billion)
  21. Europe CT Scan Market By Region, From 2016-2021 (USD Billion)
  22. Europe Melanoma Therapeutics Market By Treatment, From 2016-2021 (USD Billion)
  23. Europe early melanoma Market By Region, From 2016-2021 (USD Billion)
  24. Europe advanced melanoma Market By Region, From 2016-2021 (USD Billion)
  25. Europe Melanoma Therapeutics Market By Advanced Melanoma, From 2016-2021 (USD Billion)
  26. Europe Biological therapy Market By Region, From 2016-2021 (USD Billion)
  27. Europe Targeted therapy Market By Region, From 2016-2021 (USD Billion)
  28. Europe Surgery Market By Region, From 2016-2021 (USD Billion)
  29. Europe Chemotherapy Market By Region, From 2016-2021 (USD Billion)
  30. Europe Radiotherapy Market By Region, From 2016-2021 (USD Billion)
  31. Europe Immune therapy Market By Region, From 2016-2021 (USD Billion)
  32. U.K Melanoma Therapeutics Market By Cancer stage , From 2016-2021 (USD Billion)
  33. U.K Melanoma Therapeutics Market By Cancer type , From 2016-2021 (USD Billion)
  34. U.K Melanoma Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  35. U.K Melanoma Therapeutics Market By Treatment, From 2016-2021 (USD Billion)
  36. U.K Melanoma Therapeutics Market By Advanced Melanoma, From 2016-2021 (USD Billion)
  37. Spain Melanoma Therapeutics Market By Cancer stage , From 2016-2021 (USD Billion)
  38. Spain Melanoma Therapeutics Market By Cancer type , From 2016-2021 (USD Billion)
  39. Spain Melanoma Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  40. Spain Melanoma Therapeutics Market By Treatment, From 2016-2021 (USD Billion)
  41. Spain Melanoma Therapeutics Market By Advanced Melanoma, From 2016-2021 (USD Billion)
  42. Germany Melanoma Therapeutics Market By Cancer stage , From 2016-2021 (USD Billion)
  43. Germany Melanoma Therapeutics Market By Cancer type , From 2016-2021 (USD Billion)
  44. Germany Melanoma Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  45. Germany Melanoma Therapeutics Market By Treatment, From 2016-2021 (USD Billion)
  46. Germany Melanoma Therapeutics Market By Advanced Melanoma, From 2016-2021 (USD Billion)
  47. Italy Melanoma Therapeutics Market By Cancer stage , From 2016-2021 (USD Billion)
  48. Italy Melanoma Therapeutics Market By Cancer type , From 2016-2021 (USD Billion)
  49. Italy Melanoma Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  50. Italy Melanoma Therapeutics Market By Treatment, From 2016-2021 (USD Billion)
  51. Italy Melanoma Therapeutics Market By Advanced Melanoma, From 2016-2021 (USD Billion)
  52. France Melanoma Therapeutics Market By Cancer stage , From 2016-2021 (USD Billion)
  53. France Melanoma Therapeutics Market By Cancer type , From 2016-2021 (USD Billion)
  54. France Melanoma Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  55. France Melanoma Therapeutics Market By Treatment, From 2016-2021 (USD Billion)
  56. France Melanoma Therapeutics Market By Advanced Melanoma, From 2016-2021 (USD Billion)

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, kakatiya's empire,
Jubilee Gardens,
Hyderabad, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.